Trial description:
A Randomized, Open-label Phase 3 study of the Combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the First-line Treatment of Subjects with Chronic Lymphocytic Leukaemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Contact name:
Dr George Follows
Trial start date:
Thursday, June 28, 2018
Trial end date:
Tuesday, April 30, 2019
Trial tumour type:
Haematological
Show on Radiotherapy:
No
